Biocon Ltd - Company Profile
Powered by 
All the data and insights you need on Biocon Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Biocon Ltd Strategy Report
- Understand Biocon Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal antibodies (MAbs), rh-Insulin, and insulin analogs. The company also provides services including contract manufacturing, drug licensing, research, development and manufacturing of small and large molecules for biotechnology and pharmaceutical companies across the world. It has a manufacturing facility and R&D center at BioXcell, Malaysia. It operates overseas offices in the UK, Ireland, the US, Switzerland, the UAE, and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.
Headquarters
India
Address
20th Km, Hosur Road, Electronic City, Bangalore, Karnataka, 560100
Website
www.biocon.com
Telephone
91 80 28082808
No of Employees
3,408
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIOCON (NSE)
Revenue (2022)
$1.4B
36.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-28.6%
(2022 vs 2021)
Market Cap*
$3.8B
Net Profit Margin (2022)
XYZ
-47.7%
(2022 vs 2021)
* As of and is in US$
Biocon Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Generics: | Drug Licensing Services | InsuPen |
| Generic Formulations | Research and Development | BioMAb EGFR |
| Active Pharmaceutical Ingredients (APIs) | Contract Manufacturing Services | Nufil safe |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, Biocon Biologics entered into an agreement to sell its Indian branded formulations businesses to Eris Lifesciences for US$150 million. |
| 2024 | Contracts/Agreements | In February, Biocon Biologics entered into a five-year partnership with Sandoz AG to give Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia. |
| 2024 | Regulatory Approval | In February, the company received approval from the U.S. Food and Drug Administration for Dasatinib tablets. |
Competitor Comparison
| Key Parameters | Biocon Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Piramal Enterprises Ltd | Morepen Laboratories Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Bangalore | Mumbai | Hyderabad | Mumbai | New Delhi |
| State/Province | Karnataka | Maharashtra | Telangana | Maharashtra | Delhi |
| No. of Employees | 3,408 | 41,000 | 24,832 | 12,220 | 1,649 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kiran Mazumdar-Shaw | Chairman | Executive Board | 2020 | 70 |
| Siddharth Mittal | Director; Managing Director; Chief Executive Officer | Executive Board | 2019 | 45 |
| Peter Bains | Chief Executive Officer - Group | Senior Management | 2023 | - |
| M. B. Chinappa | Chief Financial Officer - Biocon Biologics | Senior Management | 2019 | - |
| Shreehas P. Tambe | Managing Director - Biocon Biologics Limited; Chief Executive Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward